Latest Innovation from Nucleus Biologics Enables Co-located Media & Buffer Manufacturing & Bioproduction

This session is designed for cell and gene therapy developers, process development teams, and manufacturing leaders seeking to accelerate timelines while reducing manufacturing costs. Nucleus Biologics addresses key industry challenges in media and buffer preparation, including variability, scalability, and manufacturing complexity. We will highlight the Krakatoa® K500, the first bioreactor-scale, pod-based manufacturing system designed to transform media and buffer production while improving consistency, traceability, and operational efficiency. 

The Krakatoa® K500 produces up to 500 liters of sterile solutions on-site and on-demand in under three hours. Unlike traditional manual preparation methods, the platform integrates automated processing, standardized formulations, continuous inline monitoring, and digital batch records to streamline regulatory and simplify scale-up. Combined with Nucleus Biologics’ custom media and buffer development services, QuickStart Media™, and GMP excipient manufacturing capabilities, this approach enables faster development timelines and simplifies supply chains. Together, these innovations significantly reduce manufacturing costs and support broader patient access to advanced therapies.